Tag: Stem Cells
Four months after treating them, Yasuhiro Shiga, MD, PhD, checked on his rats. Walking into the lab, he carried minimal expectations. Treating spinal cord injuries with stem cells had been tried by many people, many times before, with modest success at best. The endpoint he was specifically there to measure — pain levels — hadn’t seemed to budge in past efforts.
Early research at Mayo Clinic using stem cell therapy to treat spinal cord injuries has produced results for one patient that doctors describe as “beyond expectations.”
Japanese Researchers Will Use Stem Cells to Treat Spinal Cord Injuries in Groundbreaking Clinical...
There could a new form of treatment in Japan for spinal cord injuries if a newly-approved clinical trial hits the mark.
On Monday, a special committee of the Ministry of Health, Labor and Welfare in Japan approved a clinical research program at Tokyo’s Keio University to use induced pluripotent stem (iPS) cells to treat spinal cord injuries. According to the Nikkei Asian Review, this is a groundbreaking first-of-its-kind study. The clinical trial is expected to begin this summer.
Injuries to the spinal cord can cause permanent paralysis and even lead to death, with little to no hope of regaining lost functions once the trauma has occurred.
Dr Jerry Silver and his team at Case Western Reserve University Medical School, USA, have been working to understand why nerves that are damaged through spinal injury don’t regenerate and to identify non-invasive, easy to administer strategies that can promote robust functional recovery.
Chief among their worries is insufficient evidence that the therapy works.
Japan has approved a stem-cell treatment for spinal-cord injuries. The event marks the first such therapy for this kind of injury to receive government approval for sale to patients.
“This is an unprecedented revolution of science and medicine, which will open a new era of healthcare,” says oncologist Masanori Fukushima, head of the Translational Research Informatics Center, a Japanese government organization in Kobe that has been giving advice and support to the project for more than a decade.
BALDWIN PARK, Calif., Jan. 3, 2019 /PRNewswire/ — StemCyte is pleased to announce that the U.S. Food and Drug Administration (FDA), on December 14, 2018, approved its Phase II Investigational New Drug (IND) application for Allogeneic Human Leukocyte Antigen (HLA)-Matched Umbilical Cord Blood Mononuclear Stem Cells (UCBMNC) (MC001) for the treatment of spinal cord injury.
A/Prof James St John is an incredibly talented and innovative professor who hopes to demonstrate the endless possibilities of science.
In this presentation, Dr.Alicia Fuhrman in the Department of Rehabilitation Medicine, University of Washington, explains the complex and rapidly expanding field of stem cell medicine.
Modern medicine has still not managed to crack the problem of spinal cord injuries that result in significant paralysis or loss of functional status.
There are numerous factors that influence the inability to restore movement or autonomous bodily control to these patients. A prominent example of these is the inability to cultivate new neurons that make up and power the spinal cord.
However, some researchers have claimed that they have successfully induced ‘generic’ human stem cells to differentiate into stem cells that apply more specifically to the spine.
Derived from human pluripotent stem cells, these diverse cells advance disease modeling and may provide new, scalable source of replacement cells for spinal cord injuries
Researchers at University of California San Diego School of Medicine report that they have successfully created spinal cord neural stem cells (NSCs) from human pluripotent stem cells (hPSCs) that differentiate into a diverse population of cells capable of dispersing throughout the spinal cord and can be maintained for long periods of time.